{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
acetylcholine
to a specific field?
Status:
Investigational
Source:
NCT02340325: Phase 1 Interventional Completed Cicatrix
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Kynurenic acid is a product of the normal metabolism of amino acid L-tryptophan which has been shown to have a neuroactive profile. It exhibits activity against NMDA receptors and Neuronal acetylcholine receptor subunit alpha-7. It has been investigated as a potential therapeutic compound and as a biomarker in a number of neurological disorders. Although Kenyruic acid exhibits a poor penetration of the blood-brain barrier, it remains to be of particular interest to those researching Schizophrenia.
Status:
Investigational
Source:
NCT00001933: Phase 2 Interventional Completed Alzheimer's Disease
(1999)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Nefiracetam is a cyclic derivative of gamma-aminobutyric acid (GABA). It is thought to act by normalising dysfunctional acetylcholine, GABA and possibly monoamine neurotransmitter systems, but it may also facilitate N/L-type calcium channel opening. Nefiracetam has received attention as a treatment for seizures, depression, and dementia. Nefiracetam was found to be extremely testicular toxic in both rats and dogs; it was found to significantly decrease the levels of testicular testosterone leading to atrophy and malformation of sperm.
Status:
Investigational
Source:
INN:rivanicline [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Rivanicline (also known as RJR-2403 or TC-2403) is a partial neuronal nicotinic acetylcholine receptor agonist. This compound binds primarily to the α4β2 receptor subtype. Rivanicline was originally developed for Alzheimer’s disease and shows pronounced anti-amnesic and increased recognition memory in rats. Because rivanicline also inhibits Interleukin-8 production, it has been further developed as a potential anti-inflammatory treatment for ulcerative colitis (in which nicotine is of therapeutic value but has adverse events). Rivanicline effectively inhibited TNF- and LPS-induced IL-8 production in different cell types, without toxic effects. Rivanicline was also evaluated as a potential compound for the development of nicotinic therapeutics to treat neurological diseases in cases of compromised cholinergic neurotransmission.
Status:
Investigational
Source:
Br J Clin Pract. May 1971;25(5):233-5.: Not Applicable Human clinical trial Completed Bronchitis
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Oxotremorine, a metabolite of tremorine, is a non-hydrolyzed muscarinic acetylcholine receptor agonist used as a research tool. This compound is a muscarinic agent equal in potency to acetylcholine, but completely lacking in nicotinic activity.
Status:
Investigational
Source:
Clin Pharmacol Ther. Sep 1996;60(3):276-82.: Not Applicable Human clinical trial Completed Alzheimer Disease/blood/psychology
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Arecoline is a natural alkaloid and is an effective constituent of Areca catechu L. (Arecaceae) with various pharmacological activities including effects on nervous, cardiovascular, digestive and endocrine systems and anti-parasitic effects. Antinociception of arecoline is mediated by the activation of the muscarinic acetylcholine receptors. It was found that this compound leads to oral submucosal fibrosis and oral cancer. Lung cancer is a severe type of carcinoma with high cell motility that is difficult to treat. As a result, further studies are needed to reduce or eliminate the toxicity of the compound before developing into a new drug.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
![Structure of [3H]Pirenzepine](/img/0eba46a5-9709-4076-949b-e7336a137de2.svg?size=200&context=eaxzdafcsm)
